{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:12Z","timestamp":1787020812188,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) is a rare disease that can lead to poor quality of life, conduction disorders, arrhythmia, heart failure, and even death. Fortunately, specific treatments that can modify the natural history of the disease and the disease outcomes are now available. However, data on the prevailing patient management procedures and long-term outcomes of CA are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The Healthcare Amyloidosis European Registry (HEAR) is 34-centre registry initiated in France and structured for European expansion through the French Clinical Research Infrastructure Network\u2019s Group for Research on Amyloidosis and Care Excellence and the European Clinical Research Infrastructure Network. We expect to include 8500 patients between January 2021 and December 2027.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The HEAR has been designed to capture detailed demographic, clinical, laboratory, imaging, and therapeutic data from both suspected and confirmed cases of all cardiac amyloidosis subtypes, including wildtype transthyretin amyloidosis, variant transthyretin amyloidosis, light-chain amyloidosis, and rarer forms. This comprehensive approach has been designed to (i) improve our understanding of real-world diagnostic pathways, treatment practices, and patient outcomes and (ii) incorporate patient-centred innovations. To enhance the patient-centred nature of the registry, patient-reported outcome measures (PROMs) will be systematically collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By addressing diagnostic pathways, real-world management and PROMs and by applying technological innovations and European scalability, the next-generation HEAR is establishing itself as a valuable resource for clinical research, public health interventions, and better patient care in the field of CA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04062-y","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:03:16Z","timestamp":1761519796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network"],"prefix":"10.1186","volume":"20","author":[{"given":"Patricia","family":"R\u00e9ant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"B\u00e9zard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bodez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Bouchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Charron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Courand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dagrenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Delelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine Jobbe","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Eicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Fraix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Gellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Gueffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hag\u00e8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huttin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Jeanneteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Legallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Logeart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Inamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Marguerit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Mirailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Pezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Piriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Mouhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Tr\u00e9sorier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Von Hunolstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Salvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"4","key":"4062_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","volume":"25","author":"MD Benson","year":"2018","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215\u201319.","journal-title":"Amyloid"},{"issue":"5","key":"4062_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","volume":"43","author":"T Damy","year":"2022","unstructured":"Damy T, Kristen AV, Suhr OB, Maurer MS, Plante-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2022;43(5):391\u2013400.","journal-title":"Eur Heart J"},{"issue":"2","key":"4062_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4062_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","volume":"29","author":"M Kharoubi","year":"2022","unstructured":"Kharoubi M, Bodez D, Bezard M, Zaroui A, Galat A, Guendouz S, et al. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid. 2022;29(2):79\u201391.","journal-title":"Amyloid"},{"issue":"3","key":"4062_CR5","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ehf2.14671","volume":"11","author":"A Zaroui","year":"2024","unstructured":"Zaroui A, Kharoubi M, Gounot R, Oghina S, Degoutte C, Bezard M, et al. Prognostic mortality factors in advanced light chain cardiac amyloidosis: a prospective cohort study. ESC Heart Fail. 2024;11(3):1707\u201319.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"4062_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","volume":"4","author":"E Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC Cardio Oncol. 2022;4(4):442\u201354.","journal-title":"JACC Cardio Oncol"},{"key":"4062_CR7","doi-asserted-by":"publisher","first-page":"1124660","DOI":"10.3389\/fcvm.2023.1124660","volume":"10","author":"M Kharoubi","year":"2023","unstructured":"Kharoubi M, Bezard M, Broussier A, Galat A, Gounot R, Poullot E, et al. Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovasc Med. 2023;10:1124660.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4062_CR8","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1002\/ehf2.13652","volume":"8","author":"M Kharoubi","year":"2021","unstructured":"Kharoubi M, Bezard M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, et al. History of extracardiac\/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Fail. 2021;8(6):5501\u201312.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"4062_CR9","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.clinme.2023.100004","volume":"24","author":"CH Choy","year":"2024","unstructured":"Choy CH, Steeds RP, Pinney J, Baig S, Turvey-Haigh L, Wahid Y, et al. Extending the reach of expert amyloidosis care: a feasibility study exploring the staged implementation of a UK amyloidosis network. Clin Med (Lond). 2024;24(1):100004.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"4062_CR10","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","volume":"3","author":"T Damy","year":"2016","unstructured":"Damy T, Maurer MS, Rapezzi C, Plante-Bordeneuve V, Karayal ON, Mundayat R, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1):e000289.","journal-title":"Open Heart"},{"issue":"10","key":"4062_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","volume":"116","author":"T Damy","year":"2023","unstructured":"Damy T, Zaroui A, de Tournemire M, Kharoubi M, Gounot R, Galat A, et al. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. Arch Cardiovasc Dis. 2023;116(10):433\u201346.","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"4062_CR12","doi-asserted-by":"publisher","first-page":"e033094","DOI":"10.1161\/JAHA.123.033094","volume":"13","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Nitsche C, Porcari A, Patel RK, Razvi Y, Rauf MU, et al. Multiorgan dysfunction and associated prognosis in transthyretin cardiac amyloidosis. J Am Heart Assoc. 2024;13(4):e033094.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"4062_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1185\/03007995.2012.754349","volume":"29","author":"V Plante-Bordeneuve","year":"2013","unstructured":"Plante-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77\u201384.","journal-title":"Curr Med Res Opin"},{"issue":"9925","key":"4062_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(13)62070-X","volume":"383","author":"SC Chung","year":"2014","unstructured":"Chung SC, Gedeborg R, Nicholas O, James S, Jeppsson A, Wolfe C, et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. Lancet. 2014;383(9925):1305\u201312.","journal-title":"Lancet"},{"issue":"Suppl, 2","key":"4062_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00292-009-1182-8","volume":"30","author":"P Westermark","year":"2009","unstructured":"Westermark P. Amyloid centers in Europe: the EURAMY project. Pathologe. 2009;30(Suppl, 2):124\u201327.","journal-title":"Pathologe"},{"issue":"6","key":"4062_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1515\/cclm-2019-1007","volume":"58","author":"D Canetti","year":"2020","unstructured":"Canetti D, Rendell NB, Gilbertson JA, Botcher N, Nocerino P, Blanco A, et al. Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. Clin Chem Lab Med. 2020;58(6):948\u201357.","journal-title":"Clin Chem Lab Med"},{"issue":"16","key":"4062_CR17","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368.","journal-title":"Eur Heart J"},{"key":"4062_CR18","doi-asserted-by":"publisher","first-page":"133522","DOI":"10.1016\/j.ijcard.2025.133522","volume":"437","author":"A Jobbe-Duval","year":"2025","unstructured":"Jobbe-Duval A, Kharoubi M, Donal E, Bauer F, Broussier A, Bisson A, et al. Impact of Tafamidis on survival in elderly patients: insights from the Healthcare European Amyloidosis Registry. Int J Cardiol. 2025;437:133522.","journal-title":"Int J Cardiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04062-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:03:17Z","timestamp":1761519797000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04062-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04062-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be conducted and reporting on in accordance with the principles of the Declaration of Helsinki. The HEAR is registered with the French National Agency for the Safety of Medicines and Health (\n                      Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9\n                      (Paris, France); identifier: IDRCB 2019-A02010-57) and ClinicalTrials.gov (identifier: NCT05101304). As stated above, the HEAR protocol is strictly observational. It will not modify the patient\u2019s usual care and will not require additional consultations or examinations. The patients will be asked to give their written, informed consent for the retroprospective and prospective collection of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB has received research grants and\/or consulting fees from Alnylam, Astra Zeneca, Bristol Myer Squibb, Medtronic, and Vifor Pharma. AJD has received consulting fees from Alnylam and Pfizer. AZ has received consulting fees from Alnylam and Pfizer. DG has received consulting fees from AstraZeneca, Alnylam, and Pfizer. ED has received research grant and\/or consulting fees from GE Healthcare, Abbott, Pfizer, Alnylam, Astra Zeneca, and Bristol Myer Squibb. JI has received consulting fees from Alnylam and Pfizer. JJ has received research grants and\/or consulting fees, outside the present work, from Amgen, Biotronik, Novo Nordisk, and Pfizer. OL has received research grant and or consulting fees from Alexion, Alnylam, Amicus, AstraZeneca, Bristol Myer Squibb, Siemens healthineers, Neurimmune, and Novo Nordisk. PC reports personal fees for consultancies, outside the present work, for Amicus, Bristol Myers Squibb, Owkins, Pfizer, and Sanofi. PN has received consulting fees from Alnylam and Pfizer. PR has received research grants and\/or consulting fees from Pfizer, Alnylam, BMS, Cytokinetics, Amicus Therapeutics, and Sanofi. TD has received research grants and\/or consulting fees from Akcea, Alnylam, Alexion, AstraZeneca, Bayer, BridgeBio, Neurimmune, Novo Nordisk, and Pfizer. All other co-authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}